Compare Quest Diagnostics Inc (DGX) vs Invesco S&P 500 High Div Low Volatility ETF (SPHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Invesco S&P 500 High Div Low Volatility ETF — how do they compare? Quest Diagnostics Inc trades at $205.66 (market cap $22.80B), while Invesco S&P 500 High Div Low Volatility ETF trades at $52.22. The key difference: Quest Diagnostics Inc pays a 1.67% dividend while Invesco S&P 500 High Div Low Volatility ETF pays none, and Invesco S&P 500 High Div Low Volatility ETF is trading nearer its 52-week high, Quest Diagnostics Inc nearer its low. Which is the better fit depends on your goals.
| DGX | SPHD | |
|---|---|---|
Market Cap | $22.80B | — |
Sector | Health | — |
52-Week High | $216.02 | $52.63 |
52-Week Low | $166.42 | $46.96 |
Enterprise Value | $28.82B | — |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
SPHD trades at $52.18, up 0.69% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF focuses on high-dividend, low-volatility S&P 500 stocks, offering monthly income with a current yield around 4.5%. Recent news highlights its appeal to retirees seeking reliable income, though its long-term performance has lagged the broader market.
Outlook: SPHD provides defensive income but faces growth limitations. Opportunities include steady dividends and lower volatility; risks involve underperformance versus growth ETFs and sensitivity to interest rate changes. Investors should weigh income needs against total return expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Invesco S&P 500 High Div Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the “index Provider”) compiles, maintains and calculates the underlying index, which is designed to measure the performance of 50 least volatile high yielding constituents of the S&P 500 ® Index in the past year.
Read more on SPHD →
